Loading
Life sciences · Journal article
The Journal of Clinical Endocrinology & Metabolism · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
CONTEXT: Obesity-associated adipose tissue dysfunction is characterized by extracellular matrix (ECM) remodeling and fibrosis, where collagen VI and its bioactive cleavage peptide endotrophin have been implicated as key mediators. OBJECTIVE: Characterize collagen VI alpha-3 (COL6A3) depot-specific expression in obesity and determine whether endotrophin impairs adipocyte metabolism and insulin responsiveness. DESIGN, SETTING, AND PARTICIPANTS: COL6A3 expression was examined in paired subcutaneous (SAT) and omental adipose tissue (OAT) from 60 individuals spanning a broad Body-Mass-Index (BMI) range. Plasma endotrophin was measured in a subset of the cohort (n=42). Endotrophin effects were assessed in adipose explants, primary human and SGBS adipocytes. MAIN OUTCOME ME: asures. Depot-specific COL6A3 expression relative to BMI and endotrophin's effects on adipose tissue gene expression, GLUT4 levels, and adipocyte glucose uptake rate. RESULTS: COL6A3 expression was associated with adiposity only in SAT. BMI remained an independent predictor after adjustment for age, sex, and metabolic covariates. COL6A3 co-expression patterns were positively associated with ECM remodeling and inflammation genes in both depots, while inverse associations with lipid metabolism and insulin signaling genes were specific to SAT. Circulating endotrophin levels were associated with fat mass percentage and triglyceride-to-HDL-cholesterol ratio, but not with adipose tissue COL6A3 expression. Endotrophin treatment reduced expression of PPARγ, SLC2A4 (GLUT4), and NR3C1, decreased GLUT4 protein, and impaired adipocyte insulin-stimulated glucose uptake rate without affecting AKT phosphorylation. Endotrophin reduced PPARγ, DGAT2, and SLC2A4 expression in differentiating SGBS adipocytes. Glucocorticoids upregulated COL6A3 in both depots. CONCLUSIONS: These findings implicate COL6A3-associated ECM remodelling and endotrophin in adipose dysfunction and impaired adipocyte insulin responsiveness in obesity.